Chicago, IL, United States of America

Alessandra Mattei

This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Reata Pharmaceuticals Holdings, LLC, Abbvie Inc., Other. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alessandra Mattei. Retrieved from https://idiyas.com/inventor/alessandra-mattei

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Alessandra Mattei: Innovator in Pharmaceutical Chemistry

Introduction

Alessandra Mattei is a prominent inventor based in Chicago, IL, known for her contributions to pharmaceutical chemistry. With a total of 4 patents to her name, she has made significant strides in the field of drug development.

Latest Patents

Her latest patents include the innovative compound 2,2-difluoropropionamide derivatives of bardoxolone methyl, along with its polymorphic forms and methods of use. These inventions are pivotal in advancing therapeutic options for various medical conditions.

Career Highlights

Throughout her career, Alessandra has worked with notable companies such as Reata Pharmaceuticals Holdings, LLC and AbbVie Inc. Her work in these organizations has been instrumental in the development of new pharmaceutical products.

Collaborations

Alessandra has collaborated with esteemed colleagues, including Ahmad Y Sheikh and Xiu Chun Wang, further enhancing her research and innovation efforts.

Conclusion

Alessandra Mattei's contributions to pharmaceutical chemistry and her innovative patents underscore her role as a leading inventor in the industry. Her work continues to influence the development of new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…